Platform Wealth Management LLC Takes Position in Johnson & Johnson $JNJ

Posted by Francis Steltz on Jun 4th, 2026

Platform Wealth Management LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,518 shares of the company’s stock, valued at approximately $521,000.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Blueline Advisors LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $25,000. Abich Financial Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at $26,000. Cresta Advisors Ltd. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $26,000. DecisionPoint Financial LLC increased its stake in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the last quarter. Finally, Family CFO Inc acquired a new position in Johnson & Johnson in the fourth quarter valued at $31,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on JNJ. Citigroup upped their target price on Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $265.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Barclays upped their target price on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 15th. Finally, HSBC upped their target price on Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $253.04.

View Our Latest Report on Johnson & Johnson

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $223.60 on Thursday. The firm has a market capitalization of $538.25 billion, a PE ratio of 25.85, a P/E/G ratio of 2.18 and a beta of 0.26. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The business has a 50-day moving average of $232.25 and a two-hundred day moving average of $225.69. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s payout ratio is currently 61.97%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson reported encouraging Phase 2 results for nipocalimab in lupus, meeting the primary endpoint and showing sustained disease activity reduction through 52 weeks. Article Title
Positive Sentiment: New Sjögren’s disease data further reinforced nipocalimab’s ability to reduce autoantibodies and showed stronger response rates in patients with higher disease burden. Article Title
Neutral Sentiment: Johnson & Johnson is drawing extra investor attention, likely reflecting renewed focus on the stock after the recent pipeline updates and broader interest in defensive healthcare names. Article Title
Neutral Sentiment: Commentary on Johnson & Johnson as a potential high-growth dividend stock may be supporting the company’s income-investor appeal, but it does not appear to reflect a new operating development. Article Title
Neutral Sentiment: Scotiabank reiterated a Buy rating on Johnson & Johnson, which can help reinforce confidence in the stock among investors. Article Title

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.